IL97909A - Pharmaceutical compositions containing anti-tnf monoclonal antibodies for the treatment of acute cardiac infarct and its consequences - Google Patents

Pharmaceutical compositions containing anti-tnf monoclonal antibodies for the treatment of acute cardiac infarct and its consequences

Info

Publication number
IL97909A
IL97909A IL97909A IL9790991A IL97909A IL 97909 A IL97909 A IL 97909A IL 97909 A IL97909 A IL 97909A IL 9790991 A IL9790991 A IL 9790991A IL 97909 A IL97909 A IL 97909A
Authority
IL
Israel
Prior art keywords
consequences
treatment
pharmaceutical compositions
monoclonal antibodies
compositions containing
Prior art date
Application number
IL97909A
Other versions
IL97909A0 (en
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IL97909A0 publication Critical patent/IL97909A0/en
Publication of IL97909A publication Critical patent/IL97909A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The use of anti-TNF antibodies to treat ischaemic and its sequelae, is claimed, especially when the ischaemia is an infarct or results from transplantation.
IL97909A 1990-04-25 1991-04-22 Pharmaceutical compositions containing anti-tnf monoclonal antibodies for the treatment of acute cardiac infarct and its consequences IL97909A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4013114 1990-04-25
DE4037604A DE4037604A1 (en) 1990-04-25 1990-11-27 Use of anti-TNF antibodies to treat ischaemia and its sequelae - esp. to increase survival rate after myocardial infarct and transplants

Publications (2)

Publication Number Publication Date
IL97909A0 IL97909A0 (en) 1992-06-21
IL97909A true IL97909A (en) 1997-09-30

Family

ID=25892502

Family Applications (1)

Application Number Title Priority Date Filing Date
IL97909A IL97909A (en) 1990-04-25 1991-04-22 Pharmaceutical compositions containing anti-tnf monoclonal antibodies for the treatment of acute cardiac infarct and its consequences

Country Status (7)

Country Link
EP (1) EP0453898B1 (en)
JP (1) JPH04364133A (en)
AT (1) ATE123226T1 (en)
DE (2) DE4037604A1 (en)
DK (1) DK0453898T3 (en)
ES (1) ES2073059T3 (en)
IL (1) IL97909A (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
JP3443119B2 (en) 1989-08-07 2003-09-02 ペプテック リミテッド Tumor necrosis factor binding ligand
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
DE4307508A1 (en) * 1993-03-10 1994-09-15 Knoll Ag Use of anti-TNF antibodies as a medicine in the treatment of heart failure (heart muscle weakness)
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
TWI439284B (en) 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 Multiple variable dose therapy for the treatment of TNFα-related disorders
KR101465456B1 (en) 2005-05-16 2014-11-27 애브비 바이오테크놀로지 리미티드 Use of TNF inhibitor for treatment of erosive polyarthritis
EP2738179A1 (en) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
JOP20190162A1 (en) 2016-12-30 2019-06-27 Biocad Joint Stock Co Aqueous Pharmaceutical Composition of a Recombinant Monoclonal Antibody to TNF?

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8805792D0 (en) * 1988-03-11 1988-04-13 Celltech Ltd Medicaments
NZ229922A (en) * 1988-07-18 1992-04-28 Chiron Corp Monoclonal antibodies specifically binding cachectin (tumor necrosis factor) and compositions

Also Published As

Publication number Publication date
ATE123226T1 (en) 1995-06-15
EP0453898A3 (en) 1991-12-18
JPH04364133A (en) 1992-12-16
DE4037604A1 (en) 1991-10-31
EP0453898A2 (en) 1991-10-30
IL97909A0 (en) 1992-06-21
DK0453898T3 (en) 1995-10-09
DE59105609D1 (en) 1995-07-06
EP0453898B1 (en) 1995-05-31
ES2073059T3 (en) 1995-08-01

Similar Documents

Publication Publication Date Title
IL97909A0 (en) Anti-tnf antibodies for the treatment of ischaemias and their consequences
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
GR3029683T3 (en) CDw52-SPECIFIC ANTIBODY FOR TREATMENT OF MULTIPLE SCLEROSIS.
ATE439137T1 (en) TREATMENT OF HEMATOLOGICAL DISORDERS
NO933126L (en) Soluble ligands for CD40
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
GR3026219T3 (en) Mouse monoclonal antibodies
DE69214610D1 (en) Process for the treatment of natural gas
DE3870508D1 (en) COMPOSITION FOR TREATING THE HAIR.
GB9009106D0 (en) Processes and intermediates for synthetic antibody derivatives
DE69109401D1 (en) Aqueous compositions for the treatment of porous substrates.
MX9203629A (en) MONOCLONAL ANTIBODIES COMPOSITIONS FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF BACTERIAL INFECTIONS DUE TO GROUP B STREPTOCOCCES.
GR3018304T3 (en) Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4h-pyran-4-ones.
DE69333711D1 (en) COMPACTIN FOR TREATING IGNITIONS
ATE199321T1 (en) ANTI-IDIOTYPIC ANTIBODIES AGAINST GONOCOCCES AND METHODS AND COMPOSITIONS USING SAME.
ATE222927T1 (en) MONOCLONAL ANTIBODIES AGAINST TUMOR CYTOTOXIC FACTOR II (TCF-II)
AU653332B2 (en) Synthetic peptides which contain sequences from factor VIIa, and the use thereof
FR2704394B1 (en) Absorbable nutritional supplement for the treatment of hair and nails.
TW223019B (en)
DE68918449D1 (en) Silicon compounds for the treatment of bones.
RU93005016A (en) Immunoregulatory and neuroregulatory pentapeptides, pharmaceutical compositions based on their basis, the method of obtaining pentapeptides, the method of treatment
DE68901234D1 (en) MEDICINAL COMPOSITION FOR TREATING LUNG CLOSURE.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees